# The ATHENA COVID-19 Study

The Australians Together HEalth INitiAtive - Unlocking Queensland's Potential

Professor Kim Greaves BSc, MBBS, MD, FRCP (UK), FRACP. Consultant Cardiologist, Sunshine Coast University Hospital

# Background

- Clinical Trials (CTs) are the primary mechanism of translational research
- Lead to societal access to new medicines, procedures and diagnostics.
- CTs drive the application of evidencebased medicines and include current best practice health care.



- Globally the CTs market is worth:
  - 2019: \$47 billion
  - 2027: \$70 billion
- Australia is ranked third globally behind the USA and Germany for CT density
- Mature health system, smart regulation and incentives




#### The Problem

- Patient recruitment is the largest barrier to CT timelines
- Greatest cause of trial failure.
- Participant recruitment is typically an intensive, manual and site-specific process.



#### **Facts**



#### **Facts**

- The cost of patient recruitment represents
  - 30% of overall CT costs
  - 30% of total CT time
- Improve patient recruitment numbers by 25%
- Sector value could increase from AU\$1.1Bn to AU\$ 2.5Bn p.a.




### The Solution

#### **ATHENA Program Vision**

"The vision of the ATHENA Program is to deliver a state-wide registry containing the healthcare information and biospecimens of several million Australians across Queensland using dynamic consent to connect patients, researchers and the Clinical Trial industry. The result will be to deliver unprecedented growth in cutting edge commercial & non-profit health research, for health and economic benefits across Queensland."

# The ATHENA Program



- Patients consent primary, secondary and external registry data linked and stored by QH for research
- Patients consent to allow *future re-contact* to discuss participation in clinical trials or research studies



#### **ATHENA**


- Rapidly finding
- Right patients
- Large numbers
- For Clinical Trials

#### ATHENA PROGRAM BENEFITS

- Growth of our AU\$1.1B clinical trial market by accelerating participant recruitment,
- Enable pharmaceutical industry to undertake rapid feasibility assessments
  - Enable pharmaceutical industry to improve their trial design.
    - Greater support for local investigator-led research
    - Increased access to CTs for patients living rural, regional and remote areas
    - Increased access to CTs translates to improved health outcomes for Queenslanders
    - Promotes health literacy, education by involvement of patients
    - The ATHENA program and Dynamic Consent supports the Queensland Biobank initiative.


## Our progress.....

- 1. Pilot study 'GP Data Linkage Study'
- 2. ATHENA COVID-19 Study
- 3. High level architectural design for the ATHENA Program
- 4. Dynamic Consent Platform pilot study




# **GP Data Linkage Study**

- Majority agreeable to having data linked and used for health services analysis and research
- Majority agreeable to being contacted to discussing participation in clinical trials








# ATHENA COVID-19 study aims

- To create a cohort of all people diagnosed with COVID-19 in Queensland
- With linked primary, secondary and registry data.
- To investigate predictors of outcomes
- To provide an ongoing resource for future clinical trial recruitment



#### Part 1

- Notifiable Conditions System for all people tested positive CV19
- Linked to Emergency Department Collection
- Queensland Health Admitted
   Patient Data Collection
- Deaths Registration
- No consent

#### Part 2

- Part 1 data
- + GP data
- + Consent
  - ➤ To extract GP data and use health information including biospecimens for CV19 related research
  - To consent to recontact patients to discuss participation in clinical trials

# COMMUNICABLE DISEASES INTELLIGENCE

2021 Volume 45

https://doi.org/10.33321/

# The ATHENA COVID-19 Study: Cohort profile and first findings for people diagnosed with COVID-19 in Queensland, 1 January to 31 December 2020


Jennifer Welsh, Rosemary J Korda, Ellie Paige, Mark A Morgan, Hsei-Di Law, Tony Stanton, Zoltan MJ Bourne, M Ximena Tolosa, Kim Greaves, for the ATHENA (Australians Together Health Initiative) COVID-19 Project Team

# Part 1: Key results

- Time from symptom onset date to admission 4 days
- 21% hospitalizations: median stay 11 days
- 1.4% admitted to ICU (80% required ventilation)
- Living in a regional/remote are more likely to be admitted to hospital
- Living in a less disadvantaged area, less likely to be admitted to hospital
- Increasing age more likely to be admitted to hospital
- Smoking like to be admitted to hospital

# Part 2: ATHENA COVID-19 Study

- Contacted all patients who have had COVID-19 In Queensland
- Consent to release GP data access to biospecimens, for COVID-19 related research
- Consent to recontact to discuss participation in clinical trials
- Used e-consent



# Part 2: ATHENA COVID-19 Study

69% of respondents

consented to share full clinical data

73% of respondents

consented to be contacted for future research

83% of respondents

willing to consent via a digital platform

499


participants' GP health records collected


# Part 2: ATHENA COVID-19 Study

- Demonstrates that the public are willing to share their health information for research
- Prepared to form part of a pre-consented registry of willing participants ready to discuss CT participation
- Valuable information
  - Patient and GP attitudes towards to sharing of patient health information
  - Complexities of linking health information

#### Architecture for ATHENA program

Supported by QH Architecture and Standards Committee





How to identify the patients willing to share their data?

How to consent for patient data sharing at scale?

Dynamic Consent Platform (ATHENA)


How to retain engagement with and interest from each patient overtime?

How to efficiently recontact and recruit patients for individual research projects?

# What is Dynamic Consent?

Web-based consent platform

Desktop or hand-held Devices



#### My Consent Choices

#### My clinical data may be be used by

- Research institutes that are members of the original study
- Any study in the same research field as the original study
- Any research field

Choose consent preferences

When and why have my elements and why have my elements are supplied to the consent of the consent

Alter consent choices

Two-way communication

When and why have my electronic patient records been used				
Start Date	Research Institutions	Research Area	Ongoing	
July 2017	University of Queensland	Osteoporosis	N	
March 2018	Heart Foundation, Australia	Cardiovascular	Υ	
January 2020	Australian National University	COVID-19	Υ	
June 2020	Imperial College London	Mental Health	Υ	

New research opportunities you may be interested in


Study ID	Study Title	Who to contact for more information	website		
0001	Understanding Long COVID	Professor Colin Orona c.orona@health.qld.gov.au	www.longcov.edu.au		
0002	A new vaccine that may prevent heart attacks and strokes	Dr Andrew Theroma a.theroma@Griffith.edu.au	www.stopathero.hhs.a		

#### Research related to my clinical data

Thank you for allowing you electronic patient record to be used in this research. This is how they are making a positive impact

Sample ID	Sample Type	<b>Donation Date</b>	Research results
0001	Blood	11.11.2017	Published paper – 'Nature Genetics'
0002	Tissue	14.06.1019	Published Paper – 'BMJ Open'


# Dynamic Consent Platform MVP





## **Dynamic Consent Platform MVP**

- Testing begins shortly
- Recontacting patients who have had COVID-19
- Agreed to recontact
- Participation in UQ 'COVID OzGenetics'
- Research Project
- Learn, refine and improve the MVP



## ATHENA Program

#### **Widespread Support**



"The Queensland Clinical Networks Executive strongly supports the ATHENA program".... "It has the potential to transform healthcare and improve patient outcomes."

#### The 2021 ATHENA MRFF Frontiers bid received support from:

BDHP, AMA-Q, RDAQ, ARCS, UQ, AuSHI, QUT Centre for Healthcare Transformation, Menzies Health Institute Queensland, OQCE, ADHA, Medicines Australia, IQVIA, VIC Health, SA Health, WA Health, CSIRO, +++++

# Next steps.....

Component				
Dynamic Consent Platform	Further development of Dynamic Consent Platform (DCP)			
	Pilot DCP at large hospital			
Healthcare and GP Data linkage	Develop automated solution for retrieval of GP Information			
	Setup store for GP information and linkage with QH Health Information			
Data analytics	Develop analytics platform for identification of patients for research			



#### ATHENA Program and ATHENA COVID-19 Study team

Dr. Zoltan Bourne: GP, Medicine on Maple, GP clinic

Aaron Davies: Health Innovation Investment and Research Office

Professor Kim Greaves: Cardiologist, Sunshine Coast Hospital and Health Services

Melissa Hagan: Health Innovation Investment and Research Office
Helen Horton: Health Innovation Investment and Research Office

Amanda King: Sunshine Coast Hospital and Health Services

Professor Mark Morgan: GP, Bond University

A/Prof. Rosemary Korda: Research School Population Health, Australia National University.

Karen Thompson: Health Innovation Investment and Research Office

Thank you

#### **Funding**

Health Innovation Investment and Research Office, Queensland Health Health Improvement Unit, Queensland Health Central Queensland Sunshine Coast and Wide Bay Primary Health Network

Any questions?

